Tamsulosin as Adjunctive Therapy After Extracorporeal Shock Wave Lithotripsy for Renal Stones

• Status: Completed
• Trial end date: 2016-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Urolithiasis is a common health problem worldwide affecting approximately 10% of the population at some stage in their lives. The aim of this study is to evaluate the efficacy of adjuvant treatment with tamsulosin for improving the stone-free rate after a single session of extracorporeal shock wave lithotripsy (ESWL) in the treatment of radiopaque kidney stones.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Regional de Alta Especialidad del Bajio
• Treatments: Diclofenac; Tamsulosin

Criteria

Inclusion Criteria:

• A single radiopaque kidney stone (5-20 mm) in diameter visible on CT scan of the abdomen.

Exclusion Criteria:

• A lower calyx stone.

• A history of spontaneous stone passage.

• A previous failed ESWL.

• Treatment with alpha adrenergic antagonists, calcium channel inhibitors or steroids.

• Severe obesity (BMI≥40).

• Pregnancy.

• Serum creatinine ≥2 mg/dl.

• Renal artery aneurysm and/or abdominal aorta aneurysm.

• The presence of a ureteral stent.

• Anatomical abnormalities or previous surgery on the upper urinary tract.

• Bone deformities.

• Presence of a urinary tract infection.

• Coagulation disorders.

• Poorly controlled hypertension.